Macquarie Equities Research



The Global Utilities Specialist

GERMANY

MVV1 GR	Ν	leutral
Price (at CLOSE#, 17 Apr 2012)	€	22.80
12-month target	€	24.00
12-month TSR	%	+9.2
Valuation - DCF (WACC 7.4%, beta 1.1, ERP 5.0°	€ %, RFR 4.0%,	24.00 TGR 2.0%)
GICS sector		Utilities
Market cap	€m	1,503
30-day avg turnover	€m	0.1
Market cap	US\$m	1,975
Number shares on issue	m	65.91

Investment fundamentals

Year end 30 Sep		2011A	2012E	2013E	2014E
Revenue	m	3,590.5	3,660.6	3,827.8	3,998.0
Reported profit	m	117.2	98.3	98.7	102.6
Adjusted profit	m	108.5	98.3	98.7	102.6
EPS rep	€	1.78	1.49	1.50	1.56
EPS adj	€	1.65	1.49	1.50	1.56
EPS adj growth	%	13.9	-9.4	0.4	3.9
PER rep	х	12.8	15.3	15.2	14.6
PER adj	х	13.9	15.3	15.2	14.6
Total DPS	€	0.90	0.90	0.90	0.90
Total div yield	%	3.9	3.9	3.9	3.9
P/BV	х	1.3	1.3	1.2	1.2

MVV1 GR vs Germany DAX, & rec history



Macquarie coverage at the time or there was an embargo period. Source: FactSet, Macquarie Research, April 2012 (all figures in EUR unless noted)

Analyst(s)

Matthias Heck, CF	Α
+49 69 50957 8018	matthias.heck@macquarie.com
Atallah Estephan	
+44 20 30374 356	atallah.estephan@macquarie.com
Shai Hill	
+44 20 3037 4232	shai.hill@macquarie.com
Robert Schramm-I	Fuchs
+44 20 3037 4559	robert.schramm@macquarie.com

20 April 2012 Macquarie Capital (Europe) Limited

MVV Energie Back to reasonable territory

Event

 We were sellers during the recent share price spike, which was triggered by increased visibility of MVV's shareholder structure. Since February 22, the stock has lost 16% and fallen below our reiterated target price of €24. Consequently, we upgrade our rating to Neutral.

Impact

- Resilience of earnings: A key attraction of MVV is the resilience of operating profits and EPS, despite the current economic crisis and the absence of free CO2 allocations as of 2013. This resilience comes from cost cutting and MVV's diversified mix of regulated and non-regulated activities in the electricity, gas, district heating and environmental businesses. We also argue that the political environment for MVV remains supportive, especially for its combined head and power (CHP) and district heating businesses.
- Investment-driven growth opportunities: The MVV 2020 strategy includes €1.5bn growth capex for the current decade. Important milestones will be the new waste-to-energy plant in Plymouth (CDO 2014, €250m capex, €20m estimated EBIT in average) and the new 911MW CHP plant GKM9, COD in 2015. Hence, we expect a notable EBIT increase from ~€230m-250m over the next three years to €280m in 2014/15.
- Share overhang is a key short-term risk: GSZ (2.9% direct stake +3.4% derivatives) and EnBW (15.1+7.4%) recently unmasked higher-than-expected positions in MVV. This triggered takeover speculation, but we have consistently argued that both might rather reduce than increase their positions. We regard share overhang as a key risk for the share price.
- Valuation is high, but a PER premium is justified: The recent share price decline has reduced MVV's 2013E PER to ~15x. This is a considerable premium to the EU utilities sector's multiple of ~9x (based on our estimates). We flag that the company's defensive and diversified business model justifies a valuation premium. Our DCF value of €24 suggests a fair value 2013 PER of 16x, and a theoretical PER based on DDM works out to 17x, after assuming the earnings growth from current growth investments.

Earnings and target price revision

• There is no change to our earnings estimates and valuation.

Price catalyst

- 12-month price target: €24.00 based on a DCF methodology.
- Catalyst: Commodity prices and generation spreads, changes in shareholder structure, operating performance.

Action and recommendation

• We regard the company as attractive, given the resilience of earnings and long-term capex-driven growth. In our view, the recent share price decline has taken the valuation back to a reasonable territory, thus we upgrade to Neutral.

Please refer to the important disclosures and analyst certification on inside back cover of this document, or on our website www.macquarie.com.au/disclosures.

Macquarie Research

Important disclosures:

Recommendation definitions

Macquarie - Australia/New Zealand Outperform – return >3% in excess of benchmark return Neutral – return within 3% of benchmark return Underperform – return >3% below benchmark return

Benchmark return is determined by long term nominal GDP growth plus 12 month forward market dividend yield

Macquarie – Asia/Europe

Outperform – expected return >+10% Neutral – expected return from -10% to +10% Underperform – expected return <-10%

Macquarie First South - South Africa

Outperform – expected return >+10% Neutral – expected return from -10% to +10% Underperform – expected return <-10%

Macquarie - Canada

Outperform – return >5% in excess of benchmark return Neutral – return within 5% of benchmark return Underperform – return >5% below benchmark return

Macquarie - USA

Outperform (Buy) – return >5% in excess of Russell 3000 index return Neutral (Hold) – return within 5% of Russell 3000 index return

Underperform (Sell)- return >5% below Russell 3000 index return

Volatility index definition*

This is calculated from the volatility of historical price movements.

Very high-highest risk – Stock should be expected to move up or down 60–100% in a year – investors should be aware this stock is highly speculative.

High – stock should be expected to move up or down at least 40–60% in a year – investors should be aware this stock could be speculative.

 $\ensuremath{\text{Medium}}$ – stock should be expected to move up or down at least 30–40% in a year.

Low-medium – stock should be expected to move up or down at least 25–30% in a year.

Low – stock should be expected to move up or down at least 15–25% in a year. * Applicable to Australian/NZ/Canada stocks only

Recommendations – 12 months

Note: Quant recommendations may differ from Fundamental Analyst recommendations

Financial definitions

All "Adjusted" data items have had the following adjustments made:

Added back: goodwill amortisation, provision for catastrophe reserves, IFRS derivatives & hedging, IFRS impairments & IFRS interest expense Excluded: non recurring items, asset revals, property revals, appraisal value uplift, preference dividends & minority interests

EPS = adjusted net profit / efpowa*

number of shares

ROA = adjusted ebit / average total assets ROA Banks/Insurance = adjusted net profit /average total assets ROE = adjusted net profit / average shareholders funds Gross cashflow = adjusted net profit + depreciation *equivalent fully paid ordinary weighted average

All Reported numbers for Australian/NZ listed stocks are modelled under IFRS (International Financial Reporting Standards).

Recommendation proportions – For quarter ending 31 March 2012

	AU/NZ	Asia	RSA	USA	CA	EUR	
Outperform	53.90%	60.60%	57.50%	43.59%	66.67%	46.89% (for US coverage by MCUSA, 10.86% of stocks covered are investment banking	clients)
Neutral	31.56%	23.00%	32.50%	51.09%	30.00%	32.60% (for US coverage by MCUSA, 9.50% of stocks covered are investment banking c	lients)
Underperform	14.54%	16.40%	10.00%	5.32%	3.33%	20.51% (for US coverage by MCUSA, 1.36% of stocks covered are investment banking c	lients)

Company Specific Disclosures:

Sal Oppenheim jr & Cie KGaA and/or its affiliated entities received compensation for investment banking services from MVV Energie AG in the last 12 months.

Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/disclosures.

Analyst Certification:

The views expressed in this research accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research. The analyst principally responsible for the preparation of this research receives compensation based on overall revenues of Macquarie Group Ltd ABN 94 122 169 279 (AFSL No. 318062) (MGL) and its related entities (the Macquarie Group) and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations.

General Disclaimers:

Macquarie Securities (Australia) Ltd; Macquarie Capital (Europe) Ltd; Macquarie Capital Markets Canada Ltd; Macquarie Capital Markets North America Ltd; Macquarie Capital (USA) Inc; Macquarie Capital Securities Ltd and its Taiwan branch; Macquarie Capital Securities (Singapore) Pte Ltd; Macquarie Securities (NZ) Ltd; Macquarie First South Securities (Pty) Limited; Macquarie Capital Securities (India) Pvt Ltd; Macquarie Capital Securities (Malaysia) Sdn Bhd; Macquarie Securities Korea Limited and Macquarie Securities (Thailand) Ltd are not authorized deposit-taking institutions for the purposes of the Banking Act 1959 (Commonwealth of Australia), and their obligations do not represent deposits or other liabilities of Macquarie Bank Limited ABN 46 008 583 542 (MBL) or MGL. MBL does not guarantee or otherwise provide assurance in respect of the obligations of any of the above mentioned entities. MGL provides a guarantee to the Monetary Authority of Singapore in respect of the obligations and liabilities of Macquarie Capital Securities (Singapore) Pte Ltd for up to SGD 35 million. This research has been prepared for the general use of the wholesale clients of the Macquarie Group and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient you must not use or disclose the information in this research in any way. If you received it in error, please tell us immediately by return e-mail and delete the document. We do not guarantee the integrity of any e-mails or attached files and are not responsible for any changes made to them by any other person. MGL has established and implemented a conflicts policy at group level (which may be revised and updated from time to time) (the "Conflicts Policy") pursuant to regulatory requirements (including the FSA Rules) which sets out how we must seek to identify and manage all material conflicts of interest. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any transaction. In preparing this research, we did not take into account your investment objectives, financial situation or particular needs. Macquarie salespeople, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions which are contrary to the opinions expressed in this research. Macquarie Research produces a variety of research products including, but not limited to, fundamental analysis, macro-economic analysis, quantitative analysis, and trade ideas. Recommendations contained in one type of research product may differ from recommendations contained in other types of research, whether as a result of differing time horizons, methodologies, or otherwise. Before making an investment decision on the basis of this research, you need to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of your particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. This research is based on information obtained from sources believed to be reliable but we do not make any representation or warranty that it is accurate, complete or up to date. We accept no obligation to correct or update the information or opinions in it. Opinions expressed are subject to change without notice. No member of the Macquarie Group accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Clients should contact analysts at, and execute transactions through, a Macquarie Group entity in their home jurisdiction unless governing law permits otherwise. The date and timestamp for above share price and market cap is the closed price of the price date. #CLOSE is the final price at which the security is traded in the relevant exchange on the date indicated. **Country-Specific Disclaimers:**

Australia: In Australia, research is issued and distributed by Macquarie Securities (Australia) Ltd (AFSL No. 238947), a participating organisation of the Australian Securities Exchange. New Zealand: In New Zealand, research is issued and distributed by Macquarie Securities (NZ) Ltd, a NZX Firm. Canada: In Canada, research is prepared, approved and distributed by Macquarie Capital Markets Canada Ltd, a participating organisation of the Toronto Stock Exchange, TSX Venture Exchange & Montréal Exchange. Macquarie Capital Markets North America Ltd., which is a registered broker-dealer and member of FINRA, accepts responsibility for the contents of reports issued by Macquarie Capital Markets Canada Ltd in the United States and sent to US persons. Any person wishing to effect transactions in the securities described in the reports issued by Macquarie Capital Markets Canada Ltd should do so with Macquarie Capital Markets North America Ltd. The Research Distribution Policy of Macquarie Capital Markets Canada Ltd is to allow all clients that are entitled to have equal access to our research. United Kingdom: In the United Kingdom, research is issued and

Macquarie Research

distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated by the Financial Services Authority (No. 193905). Germany: In Germany, this research is issued and/or distributed by Macquarie Capital (Europe) Limited, Niederlassung Deutschland, which is authorised and regulated by the UK Financial Services Authority (No. 193905). and in Germany by BaFin. France: In France: In France, research is issued and distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated in the United Kingdom by the Financial Services Authority (No. 193905). Hong Kong & Mainland China: In Hong Kong, research is issued and distributed by Macquarie Capital Securities Ltd, which is licensed and regulated by the Securities and Futures Commission. In Mainland China, Macquarie Securities (Australia) Limited Shanghai Representative Office only engages in nonbusiness operational activities excluding issuing and distributing research. Only non-A share research is distributed into Mainland China by Macquarie Capital Securities Ltd. Japan: In Japan, research is issued and distributed by Macquarie Capital Securities (Japan) Limited, a member of the Tokyo Stock Exchange, Inc. and Osaka Securities Exchange Co. Ltd (Financial Instruments Firm, Kanto Financial Bureau (kin-sho) No. 231, a member of Japan Securities Dealers Association and The Financial Futures Association of Japan and Japan Securities Investment Advisers Association). India: In India, research is issued and distributed by Macquarie Capital Securities (India) Pvt Ltd., 92, Level 9, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051, India, which is a SEBI registered Stock Broker having membership with National Stock Exchange of India Limited (INB231246738) and Bombay Stock Exchange Limited (INB011246734). Malaysia: In Malaysia, research is issued and distributed by Macquarie Capital Securities (Malaysia) Sdn. Bhd. (Company registration number: 463469-W) which is a Participating Organisation of Bursa Malaysia Berhad and a holder of Capital Markets Services License issued by the Securities Commission. **Taiwan**: Information on securities/instruments that are traded in Taiwan is distributed by Macquarie Capital Securities Ltd, Taiwan Branch, which is licensed and regulated by the Financial Supervisory Commission. No portion of the report may be reproduced or quoted by the press or any other person without authorisation from Macquarie. Nothing in this research shall be construed as a solicitation to buy or sell any security or product. Research Associate(s) in this report who are registered as Clerks only assist in the preparation of research and are not engaged in writing the research. **Thailand**: In Thailand, research is produced with the contribution of Kasikorn Securities Public Company Limited, issued and distributed by Macquarie Securities (Thailand) Ltd. Macquarie Securities (Thailand) Ltd. is a licensed securities company that is authorized by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is an exchange member of the Stock Exchange of Thailand. Macquarie Securities (Thailand) Limited and Kasikorn Securities Public Company Limited have entered into an exclusive strategic alliance agreement to broaden and deepen the scope of services provided to each parties respective clients. The strategic alliance does not constitute a joint venture. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. Macquarie Securities (Thailand) Ltd does not endorse the result of the Corporate Governance Report of Thai Listed Companies but this Report can be accessed at: http://www.thaiiod.com/en/publications.asp?type=4. South Korea: In South Korea, unless otherwise stated, research is prepared, issued and distributed by Macquarie Securities Korea Limited, which is regulated by the Financial Supervisory Services. Information on analysts in MSKL is disclosed at http://dis.kofia.or.kr/fs/dis2/fundMgr/DISFundMgrAnalystPop.jsp?companyCd2=A03053&pageDiv=02. South Africa: In South Africa, research is issued and distributed by Macquarie First South Securities (Pty) Limited, a member of the JSE Limited. Singapore: In Singapore, research is issued and distributed by Macquarie Capital Securities (Singapore) Pte Ltd (Company Registration Number: 198702912C), a Capital Markets Services license holder under the Securities and Futures Act to deal in securities and provide custodial services in Singapore. Pursuant to the Financial Advisers (Amendment) Regulations 2005, Macquarie Capital Securities (Singapore) Pte Ltd is exempt from complying with sections 25, 27 and 36 of the Financial Advisers Act. All Singapore-based recipients of research produced by Macquarie Capital (Europe) Limited, Macquarie Capital Markets Canada Ltd, Macquarie First South Securities (Pty) Limited and Macquarie Capital (USA) Inc. represent and warrant that they are institutional investors as defined in the Securities and Futures Act. United States: In the United States, research is issued and distributed by Macquarie Capital (USA) Inc., which is a registered broker-dealer and member of FINRA. Macquarie Capital (USA) Inc, accepts responsibility for the content of each research report prepared by one of its non-US affiliates when the research report is distributed in the United States by Macquarie Capital (USA) Inc. Macquarie Capital (USA) Inc.'s affiliate's analysts are not registered as research analysts with FINRA, may not be associated persons of Macquarie Capital (USA) Inc., and therefore may not be subject to FINRA rule restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. Any persons receiving this report directly from Macquarie Capital (USA) Inc. and wishing to effect a transaction in any security described herein should do so with Macquarie Capital (USA) Inc. Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/research/disclosures, or contact your registered representative at 1-888-MAC-STOCK, or write to the Supervisory Analysts, Research Department, Macquarie Securities, 125 W.55th Street, New York, NY 10019. © Macquarie Group

Auckland	Bangkok	Calgary	Denver	Frankfurt	Geneva	Hong Kong
Tel: (649) 377 6433	Tel: (662) 694 7999	Tel: (1 403) 218 6650	Tel: (303) 952 2800	Tel: (069) 509 578 000	Tel: (41) 22 818 7777	Tel: (852) 2823 3588
Jakarta Tel: (62 21) 515 1818	Johannesburg Tel: (2711) 583 2000	Kuala Lumpur Tel: (60 3) 2059 8833	London Tel: (44 20) 3037 2000	Manila Tel: (63 2) 857 0888	Melbourne Tel: (613) 9635 8139	Montreal Tel: (1 514) 925 2850
Mumbai	Munich	New York	Paris	Perth	Seoul	Shanghai
Tel: (91 22) 6653 3000	Tel: (089) 2444 31800	Tel: (1 212) 231 2500	Tel: (33 1) 7842 3823	Tel: (618) 9224 0888	Tel: (82 2) 3705 8500	Tel: (86 21) 6841 3355
Singapore	Sydney	Taipei	Tokyo	Toronto		
Tel: (65) 6601 1111	Tel: (612) 8232 9555	Tel: (886 2) 2734 7500	Tel: (81 3) 3512 7900	Tel: (1 416) 848 3500		

Available to clients on the world wide web at www.macquarieresearch.com and through Thomson Financial, FactSet, Reuters, Bloomberg, CapitalIQ and TheMarkets.com.

Macquarie **Equities Research**



EMEA Research

Heads of Equity Research	
John O'Connell (Global Co – Head) David Rickards (Global Co – Head) Julian Wentzel (Europe/South Africa) Shai Hill (Europe) George Brits (South Africa)	(612) 8232 7544 (612) 8237 1159 (44 20) 3037 4274 (44 20) 3037 4232 (2711) 583 2223
Consumer Staples	
Food & Beverages Wynand van Zyl (Johannesburg) Sreedhar Mahamkali (London)	(2711) 583 2323 (44 20) 3037 4016
Consumer Discretionary	
Retailing Stephen Carrott (Johannesburg) Sreedhar Mahamkali (London) Robert Joyce (London)	(2711) 583 2211 (44 20) 3037 4016 (44 20) 3037 4355
Energy	
Jason Gammel (Global) David Farrell (London) Mark Wilson (London) Marc Kofler (London)	(44 20) 3037 4085 (44 20) 3037 4465 (44 20) 3037 4466 (44 20) 3037 1909
Alternative Energy	
Shai Hill (Europe) Robert Schramm-Fuchs (Europe)	(44 20) 3037 4232 (44 20) 3037 4559
Financials	
Diversified Financials Elan Levy (Johannesburg) Neil Welch (London)	(27 11) 583 2165 (44 20) 3037 4272
Banks Edward Firth (Europe) Charles Russell (Johannesburg) Benjie Creelan-Sandford (London) Thomas Stoegner (London) Piers Brown (London)	(44 20) 3037 4077 (27 11) 583 2326 (44 20) 3037 4081 (44 20) 3037 4532 (44 20) 3037 4044
Insurance Hadley Cohen (London)	(44 20) 3037 4078
Industrials	
Capital Goods Peter Steyn (Johannesburg) Sam Dobson (London)	(2711) 583 2337 (44 20) 3037 1901

Industrials - cont

(49 69) 50957 8014
(49 69) 50957 8026
(49 69) 50957 8129
ıre
(44 20) 3037 4240
(2711) 583 2337
aging/Paper &
on Materials
(2711) 583 2248
(2711) 583 2337
(49 69) 50957 8017
(49 69) 50957 8024
(49 69) 50957 8024
(44 20) 3037 4359
(44 20) 3037 2637
(618) 9224 0607
(2711) 583 2280
(2711) 583 2318
(2711) 583 2208 (2711) 583 2307
(612) 8232 9834
(•••) ••••
(2711) 583 2305
'S
(2711) 583 2209
(44 20) 3037 4509
(2711) 583 2305
(2711) 583 2305
(44 20) 3037 4099
(44 20) 3037 4099

Utilities

Shai Hill (London) Atallah Estephan Matthias Heck (Fr	(London)	(44 20) 3037 4232 (44 20) 3037 4356 (49 69) 50957 8018			
Commodities	& Preciou	s Metals			
Jim Lennon (Lond Colin Hamilton (L Duncan Hobbs (L Hayden Atkins (L Ryan Belshaw (Lo Kona Haque (Lond Chris Gadd (Lond Bonnie Liu (Singa Graeme Train (Sh Angela Bi (Shang	ondon) ondon) ondon) ondon) don) lon) ipore) nanghai)	(44 20) 3037 4271 (44 20) 3037 4061 (44 20) 3037 4497 (44 20) 3037 4476 (44 20) 3037 2732 (44 20) 3037 2732 (44 20) 3037 1957 (65) 6601 0144 (86 21) 2412 9035 (86 21) 2412 9035			
European Macro Group					
Economics & Daniel McCormac Christian Davies (Strategy George Brits (Sou	ck (Europe) (London)	(852) 3922 4073 (44 20) 3037 4037 (2711) 583 2223			
Quantitative Gurvinder Brar (Global) James Murray (London) Inez Khoo (London) George Ssali (Johannesburg)		(44 20) 3037 4036 (44 20) 3037 1976 (44 20) 3037 2640 (2711) 583 2364			
Find our rese	Find our research at				
Macquarie:	arie.com.au/research				
Thomson:	n.com/financial				

Macquarie:	www.macquarie.c	om.au/research
Thomson:	www.thomson.com	m/financial
Reuters:	www.knowledge.r	euters.com
Bloomberg:	MAC GO	
Factset:	http://www.factset	com/home.aspx
CapitalIQ	www.capitaliq.com	n
TheMarkets.com	www.themarkets.	com
Contact Gareth W	arfield for access	(612) 8232 3207
F 1 = 11 = 1 = 1 =		

Email addresses

FirstName.Surname@macquarie.com eg. David.Rickards@macquarie.com

Equities	
Stevan Vrcelj (Global Head)	(612) 8232 5999
Duarte Da Silva (Johannesburg)	(2711) 583 2000
UK Trading	
Richard Bateson (London)	(44 20) 3037 4821
Julian Parmenter (London)	(44 20) 3037 4826
Thorsten Ackermann (London)	(44 20) 3037 4908
Colin Reed (London)	(44 20) 3037 4982
Robert Tappin (London)	(44 20) 3037 4827
Wayne Drayton (London)	(44 20) 3037 4980
Marc Crome (London)	(44 20) 3037 4778
UK Sales Trading	. ,
Daryl Bowden (London)	(44 20) 3037 4973
Greg Hill (London)	(44 20) 3037 4757
Drew Hendrickson (London)	(44 20) 3037 4754
James Buckley (London)	(44 20) 3037 4780
Jim Dixon (London)	(44 20) 3037 4949
Simona Casella (London)	(44 20) 3037 1721
KC O'Rourke (London)	(44 20) 3037 4910
Edward Robinson (London)	(44 20) 3037 4979
Danny Want (London)	(44 20) 3037 4847
US Sales Trading	, , , , , , , , , , , , , , , , , , ,
Chris Reale (New York)	(1 212) 231 2555
Guy Devereux (New York)	(1 212) 231 2555

....

Germany Trading	
Elvis Javor (Frankfurt)	(49 69) 50957 8654
Germany Sales Trading	
Ralf Loke (Frankfurt) Marcus Dunne (Frankfurt)	(49 69) 50957 8833 (49 69) 50957 8831
EU Cash Sales	
Charles Nelson (London) Richard Alderman (London) Sam Bygott-Webb (London) Luke Ahern (London) Matthew Camacho (London) Ed Reekie (London) Jacob Potts (London) Charles Lesser (London) James Lumby (London) Leon Caine (London) Will Fairley (London) Karl Filbert (Frankfurt) Thomas Auschill (Frankfurt) Markus Geisbuesch (Frankfurt) Holger Hoepfner (Zurich)	(44 20) 3037 4832 (44 20) 3037 4875 (44 20) 3037 4767 (44 20) 3037 4960 (44 20) 3037 4957 (44 20) 3037 4957 (44 20) 3037 4929 (44 20) 3037 4929 (44 20) 3037 4846 (44 20) 3037 4787 (49 69) 50957 8651 (49 69) 50957 8168 (49 69) 50957 8709 (41 44) 564 0220

EU Cash Sales - cont

Lo ousil oules com	
Martin Pommier (New York) Jan Halaska (Boston) Chris Carr (New York) Doug Stone (New York)	(1 212) 231 8054 (1 617) 598 2503 (1 212) 231-6398 (1 212) 231 2606
South Africa Sales	
Franco Lorenzani (Johannesburg) William Ridge (Johannesburg) Liam Graham (London) Carleen Sobczyk (London) Nazmeera Moola (Cape Town) Russell Fryer (New York) South Africa Sales Trading	(2711) 583 2014 (2711) 583 2060 (44 20) 3037 4836 (44 20) 3037 4988 (2721) 813 2725 (1 212) 231 2504
Harry Ioannou (Johannesburg) Jesse Ushewokunze (Johannesburg) Keith Thompson (Johannesburg) Martin Hughes (Johannesburg) Marcello Damilano (Johannesburg) Roland Wood (Cape Town)	(2711) 583 2015 (2711) 583 2017 (2711) 583 2017 (2711) 583 2018 (2711) 583 2019 (2711) 583 2018 (2721) 813 2611